Total Payments
$383,286
2024 Payments
$47,185
Companies
30
Transactions
463
Medicare Patients
756
Medicare Billing
$117,200
Payment Breakdown by Category
Other$184,656 (48.2%)
Consulting$135,123 (35.3%)
Travel$42,373 (11.1%)
Food & Beverage$15,243 (4.0%)
Research$5,851 (1.5%)
Education$40.77 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $173,731 | 48 | 45.3% |
| Consulting Fee | $135,123 | 79 | 35.3% |
| Travel and Lodging | $42,373 | 138 | 11.1% |
| Food and Beverage | $15,243 | 167 | 4.0% |
| Honoraria | $10,925 | 3 | 2.9% |
| Unspecified | $5,851 | 23 | 1.5% |
| Education | $40.77 | 5 | 0.0% |
Payments by Type
General
$377,435
440 transactions
Research
$5,851
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $116,663 | 101 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $115,478 | 101 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $35,828 | 52 | $0 (2021) |
| AbbVie, Inc. | $27,638 | 67 | $0 (2018) |
| Celgene Corporation | $21,653 | 12 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $16,070 | 34 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $8,096 | 8 | $0 (2023) |
| AstraZeneca UK Limited | $5,909 | 17 | $0 (2021) |
| TAIHO ONCOLOGY, INC. | $5,719 | 7 | $0 (2024) |
| Fosun Pharma USA Inc. | $5,578 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,185 | 57 | JAZZ PHARMACEUTICALS INC. ($34,991) |
| 2023 | $99,826 | 96 | Jazz Pharmaceuticals Inc. ($68,747) |
| 2022 | $47,418 | 37 | E.R. Squibb & Sons, L.L.C. ($26,477) |
| 2021 | $29,366 | 27 | E.R. Squibb & Sons, L.L.C. ($13,195) |
| 2020 | $9,673 | 10 | AstraZeneca Pharmaceuticals LP ($3,709) |
| 2019 | $43,226 | 61 | E.R. Squibb & Sons, L.L.C. ($21,611) |
| 2018 | $46,452 | 55 | E.R. Squibb & Sons, L.L.C. ($14,869) |
| 2017 | $60,139 | 120 | AbbVie, Inc. ($17,083) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $54.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $44.42 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $620.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $9.00 | General |
| 12/04/2024 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $118.16 | General |
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/15/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $164.31 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/15/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $855.00 | General |
| 10/31/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| 10/31/2024 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | Cash or cash equivalent | $251.90 | General |
| 10/31/2024 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | Cash or cash equivalent | $66.60 | General |
| 10/23/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| 10/19/2024 | Galvanize Therapeutics, Inc | ALIYA SYSTEM (Device) | Food and Beverage | In-kind items and services | $169.34 | General |
| Category: PULSED ELECTRIC FIELD | ||||||
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Respiratory | ||||||
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | Cash or cash equivalent | $926.95 | General |
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Food and Beverage | Cash or cash equivalent | $144.10 | General |
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | Cash or cash equivalent | $129.34 | General |
| 09/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $612.95 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $35.47 | General |
| Category: Oncology | ||||||
| 09/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $9.97 | General |
| Category: Oncology | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STRATOS 1 Tralokinumab in Asthma Ph 3 Pivotal Study 1, A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist | AstraZeneca UK Limited | $3,920 | 4 |
| A randomised double blind placebo controlled parallel group multicentre phase III study to evaluate the efficacy and safety of 2 doses of benralizumab MEDI 563 in patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD with a history of COPD exacerbations GALATHEA | AstraZeneca UK Limited | $379.94 | 2 |
| A Multicentre Randomized Double blind Parallel Group Placebocontrolled Phase III Efficacy and Safety Study of Benralizumab MEDI 563 Added to High dose Inhaled Corticosteroid Plus Long acting 2 Agonist in Patients with Uncontrolled Asthma CALIMA | AstraZeneca UK Limited | $175.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 152 | 276 | $91,403 | $26,504 |
| 2022 | 3 | 192 | 319 | $104,045 | $30,027 |
| 2021 | 4 | 211 | 345 | $117,303 | $35,685 |
| 2020 | 7 | 201 | 327 | $100,220 | $24,985 |
Total Patients
756
Total Services
1,267
Medicare Billing
$117,200
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 65 | 157 | $54,008 | $16,346 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 57 | 89 | $22,695 | $6,184 | 27.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 30 | 30 | $14,700 | $3,974 | 27.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 71 | 140 | $48,160 | $14,774 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 78 | 136 | $34,769 | $9,515 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 43 | 43 | $21,116 | $5,738 | 27.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 76 | 169 | $58,136 | $18,729 | 32.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 60 | 60 | $29,400 | $8,247 | 28.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 64 | 105 | $26,775 | $7,761 | 29.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 11 | $2,992 | $947.95 | 31.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 59 | 123 | $42,312 | $10,348 | 24.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 47 | 79 | $20,145 | $4,615 | 22.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 34 | 34 | $16,706 | $4,208 | 25.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 46 | $11,500 | $3,380 | 29.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 17 | 17 | $4,624 | $1,218 | 26.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 17 | $2,958 | $815.33 | 27.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 11 | 11 | $1,975 | $400.95 | 20.3% |
About Dr. Neal Ready, MD
Dr. Neal Ready, MD is a Medical Oncology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932156197.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neal Ready, MD has received a total of $383,286 in payments from pharmaceutical and medical device companies, with $47,185 received in 2024. These payments were reported across 463 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($173,731).
As a Medicare-enrolled provider, Ready has provided services to 756 Medicare beneficiaries, totaling 1,267 services with total Medicare billing of $117,200. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Durham, NC
- Active Since 05/30/2006
- Last Updated 09/17/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1932156197
Products in Payments
- ZEPZELCA (Drug) $116,605
- Abraxane (Drug) $21,053
- OPDIVO (Biological) $17,788
- LIBTAYO (Biological) $10,326
- TEZSPIRE (Biological) $7,313
- TECENTRIQ (Biological) $4,223
- IMFINZI (Drug) $3,261
- RYBREVANT (Drug) $1,760
- ZYKADIA (Drug) $293.07
- MEKINIST (Drug) $257.89
- Avastin (Biological) $238.99
- ADCETRIS (Biological) $198.38
- ALIYA SYSTEM (Device) $169.34
- Alecensa (Biological) $146.53
- Enhertu (Drug) $130.81
- Rybelsus (Drug) $125.00
- COSELA (Drug) $117.48
- AxoGuard Nerve Protector (Device) $96.19
- Ozempic (Drug) $73.36
- KEYTRUDA (Biological) $49.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Durham
Dr. Thomas Leblanc, Md, Ma, MD, MA
Medical Oncology — Payments: $1.5M
Medical Oncology $1.5M
Andrew Armstrong, Md, MD
Medical Oncology — Payments: $486,009
Medical Oncology $486,009
Dr. Michael Harrison, M.d, M.D
Medical Oncology — Payments: $276,555
Medical Oncology $276,555
Nelson Chao, Md, MD
Medical Oncology — Payments: $79,858
Medical Oncology $79,858
Dr. Sundhar Ramalingam, M.d, M.D
Medical Oncology — Payments: $68,550
Medical Oncology $68,550
Dr. Gerard Blobe, M.d, M.D
Medical Oncology — Payments: $55,242
Medical Oncology $55,242